GH
Guardant Health, Inc.
Nasdaq: GH · Palo Alto, CA · Healthcare
Market Cap$17.10B
Cash$1.86Bmost recent
Runway85 mo$65.6M Q burn
P/E (TTM)—EPS $-3.32
52-Wk Range—
Avg Volume—3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
No price data available.
Pipeline
Drug candidates sponsored by Guardant Health · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| N/A | Unnamed | Non-small Cell Lung Cancer Metastatic | Terminated | 2019-09-01past | 1 | |
| N/A | Unnamed | Non-Hematologic Malignancy | Completed | 2020-02-01past | 1 | |
| N/A | Unnamed | Non-Small Cell Lung Cancer | Completed | 2020-11-23past | 1 | |
| N/A | Unnamed | Advanced Breast Cancer | Completed | 2022-03-17past | 1 | |
| N/A | Unnamed | Colorectal Cancer | Active, not recruiting | 2024-03-20past | 1 | |
| N/A | Unnamed | Lung Cancer | Active, not recruiting | 2026-12-31 | 1 | |
| N/A | Unnamed | Colo-rectal Cancer | Not yet recruiting | 2027-12 | 1 | |
| N/A | Unnamed | Bladder Carcinoma+15 more | Recruiting | 2029-08 | 1 | |
| N/A | Unnamed | Colo-rectal Cancer | Recruiting | 2030-09-01 | 1 | |
| N/A | Unnamed | Non-small Cell Lung Cancer+2 more | Recruiting | 2030-12-30 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for GH. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.